SCHEMBL25754747

SCHEMBL25754747

COc1ccc([N+](=O)[O-])cc1S(=O)(=O)Nc1cccc(C(C)(C)C)c1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALPL P05186 3/20 0.55
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
POLB P06746 2/20 0.52
TDP1 Q9NUW8 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
ALDH1A1 P00352 2/20 0.50
ALOX12 P18054 1/20 0.49
HPGD P15428 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
MAPT P10636 1/20 0.48
TBXA2R P21731 1/20 0.47
LMNA P02545 1/20 0.46
HTR6 P50406 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754693 0.87 POLB (0.55) ALPLMEN1KMT2APOLBSMN1; SMN2
SCHEMBL25754681 0.86 MEN1 (0.73) ALPLMEN1KMT2APOLBTDP1
SCHEMBL25754684 0.86 HPGD (0.62) ALPLMEN1KMT2APOLBSMN1; SMN2
SCHEMBL26118718 0.82 ALPL (0.64) ALPLMEN1KMT2ATDP1MAPT
SCHEMBL25754683 0.82 POLB (0.57) ALPLMEN1KMT2APOLBTDP1
SCHEMBL12368213 0.81 SMN1; SMN2 (0.67) ALPLMEN1KMT2APOLBSMN1; SMN2
SCHEMBL23846535 0.81 ALPL (0.59) ALPLMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL25754730 0.81 MEN1 (0.61) ALPLMEN1KMT2APOLBSMN1; SMN2
SCHEMBL25754679 0.80 SMN1; SMN2 (0.64) ALPLMEN1KMT2APOLBSMN1; SMN2
SCHEMBL25754741 0.79 HPGD (0.57) ALPLMEN1KMT2APOLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 ALPL 3721/4885MEN1 3902/4885KMT2A 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.